NCT06322147 2024-03-20
Chemotherapy With Cetuximab as Conversion Therapy in RAS/BRAF WT Unresectable Liver Metastasis Right-sided Colon Cancer
Qilu Hospital of Shandong University
Unknown
Clinical Trials
68 trialsNCT05291156 2024-02-01
CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy
University of Campania Luigi Vanvitelli
Phase 2 Unknown
NCT04034459 2023-11-14
AIO-KRK-0116
Ludwig-Maximilians - University of Munich
Phase 2 Unknown
NCT06118047 2023-11-07
COSTIC
Sun Yat-sen University
Phase 2 Unknown
NCT04262635 2023-08-02
C-CLASSIC
Sun Yat-sen University
Phase 3 Unknown
NCT04189055 2023-06-12
CETIDYL
Hôpital Franco-Britannique-Fondation Cognacq-Jay
Phase 2 Unknown
NCT05160896 2023-06-08
SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT03391934 2023-04-05
Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer
Cinnagen
Phase 3 Unknown
NCT05799443 2023-04-05
Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT05745857 2023-02-27
SLURP
University Medical Center Groningen
Phase 2 Unknown
NCT05684211 2023-02-01
A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer
Shanghai Celfuture Biotech Co., Ltd.
Phase 2 Unknown
NCT05497336 2022-09-30
A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Unknown
NCT05155124 2022-09-13
Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1 Unknown
NCT05019534 2022-05-19
Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer
West China Hospital
Phase 1 Unknown
NCT03457896 2022-03-31
Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status
NSABP Foundation Inc
Phase 2 Unknown
NCT02675946 2022-01-26
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
Curegenix Inc.
Phase 1 Unknown
NCT05103020 2021-11-02
Phase II Study Comparing Conversion Rate to Surgery With Hepatic Arterial Infusion Chemotherapy to Systemic Chemotherapy in Patients With Non Resectable Liver-only Colorectal Metastases
Yonsei University
Phase 2 Unknown
NCT05074966 2021-10-12
The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts
ChineseAMS
Phase 3 Unknown
NCT02826837 2021-10-06
LEAC-102 for Advanced Colorectal Cancer
Taiwan Leader Biotech Corp.
Phase 1/2 Unknown
NCT04241731 2021-08-30
A Study of Cetuximab Plus Raltitrexed for Maintenance Treatment in Advanced Colorectal Cancer
Jiangsu Cancer Institute & Hospital
Phase 2 Unknown
NCT04466254 2021-08-23
Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 2 Unknown
NCT03727763 2021-08-19
Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT)
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT02942706 2021-04-30
Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC
Ruijin Hospital
Phase 2/3 Unknown
NCT04832776 2021-04-06
FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases
Fudan University
Phase 2 Unknown
NCT04833036 2021-04-06
c-CetuIRI Versus Ersecond-line Irinotecan s-IRI-CetuIRI
Fudan University
Phase 2 Unknown
NCT04668976 2020-12-21
A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma
Benaroya Research Institute
Phase 2 Unknown
NCT03608046 2020-10-22
AVETUXIRI
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Unknown
NCT04525326 2020-08-25
Conversion Therapy of RAS/BRAF Wild-Type Right-sided Colon Cancer Patients With Initially Unresectable Liver Metastases
Fudan University
Phase 3 Unknown
NCT04509635 2020-08-12
Cetuximab Re-challenge for Colorectal Cancer Liver Metastasis
Fudan University
Phase 3 Unknown
NCT02123381 2020-03-17
Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Sichuan Cancer Hospital and Research Institute
Phase 2 Unknown
NCT03491709 2019-10-31
A Preliminary Clinical Study on the Pharmacokinetics and Safety of CDP1 in Patients With Advanced CRC or HNSCC
Dragonboat Biopharmaceutical Company Limited
Phase 1 Unknown
NCT01923987 2019-09-20
Short Course Radiotherapy Followed Intensive Chemotherapy With Delayed Surgery for Rectal Cancer With Synchronous Distant Metastasis
Korea Cancer Center Hospital
Phase 2 Unknown
NCT01802645 2019-09-11
CELIM2
Technische Universität Dresden
Phase 2 Unknown
NCT03944252 2019-07-26
CARACAS
Gruppo Oncologico del Nord-Ovest
Phase 2 Unknown
NCT03923036 2019-04-22
AVOCETTE
University Hospital, Caen
Unknown
NCT02636088 2018-09-21
LERFOX-C
Karolinska University Hospital
Phase 2 Unknown
NCT03356158 2018-09-17
A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal Cancer
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 1 Unknown
NCT02836847 2018-05-07
Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
Shanghai Jiao Tong University School of Medicine
Phase 2 Unknown
NCT02296203 2018-02-15
CRICKET
Gruppo Oncologico del Nord-Ovest
Phase 2 Unknown
NCT03401957 2018-01-17
The Emergence of RAS Mutations in Metastatic Colorectal Cancer Patients Receiving Cetuximab Treatment
National Health Research Institutes, Taiwan
Unknown
NCT03126708 2018-01-04
Cetuximab in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Cisplatin Alone for the First-line Treatment of Metastatic Esophageal Squamous Cell Carcinoma
Peking University
Phase 2 Unknown
NCT02717923 2017-10-23
A Single Arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Maintenance Treatment With Capecitabine Plus Cetuximab in Metastatic Colorectal Cancer
Huazhong University of Science and Technology
Phase 2 Unknown
NCT02978313 2016-11-30
Cetuximab Monotherapy Maintenance Treatment in mCRC
Ruijin Hospital
Phase 2/3 Unknown
NCT02071069 2015-11-18
Efficacy and Tolerance of Maintenance Therapy in Patients With Incurable Advanced Colorectal Cancer
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT02515734 2015-08-05
DEEPER
Japan Clinical Cancer Research Organization
Phase 2 Unknown
NCT01943786 2015-03-17
BEAMING
Grupo Hospital de Madrid
Unknown
NCT00425425 2014-05-01
Cetuximab, Oxaliplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Esophageal Cancer
Technical University of Munich
Phase 1/2 Unknown
NCT00433927 2014-03-14
5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)
Ludwig-Maximilians - University of Munich
Phase 3 Unknown
NCT00795301 2014-01-14
A Study of Radiotherapy in Rectal Cancer Using Oxaliplatin, Capecitabine With or Without Cetuximab
National University Hospital, Singapore
Phase 2 Unknown
NCT01315990 2013-12-18
DERMATUX
Johannes Gutenberg University Mainz
Phase 4 Unknown